维普中文期刊产品整合服务
25篇 您的检索式:作者名="UTAS C"
    题名 作者 年代 出处 被引量
1Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure显示文摘长期的心失败(CHF ) 代表住院和死亡的一个主要原因。最近的证据表演那新奇 biomarkers 象 tumorigenicity (sST2 ) 的可溶的抑制那样,生长区别 factor-15 (GDF-15 ) ,可溶的尿激 plasminogen 使活跃之物受体(suPAR ) 和心类型丰满的酸绑定蛋白质(H-FABP ) 被相关与煽动性并且在 CHF 病人的 ischemic 回答。在这研究,我们检验了禁止了 激活hyperpolarization 的周期的核苷酸门隧道的 Ivabradine 的效果( HCN 隧道,也叫的滑稽电流我 从而导致选择心率减小的 f ),和改进的心肌的氧在心脏的 biomarkers sST2 上供应, GDF-15 ,在在 Jena 的大学医院的 50 个 CHF 病人的 suPAR 和 H-FABP 。病人们基于 CHF 的病原学被划分成三个组:扩大心肌症(DCM, n=20 ) , ischemic 心肌症(ICM, n=20 ) 并且高血压的心肌症(HCM, n=10 ) 。病人是管理 Ivabradine (5 mg,为 3 个月的出价,和 7.5 mg 期望推进 3 个月) 。心血管的 biomarkers 的分析在基线以及在 3 月、 6 月的后续被执行。在 6 月的后续, GDF-15 层次显著地与基线层次(P=0.0215 ) 相比被减少,显示在心脏的改变的进步的减小。H-FABP 集中在与 ICM (1.89 对 3.24 g/mL ) 和 HCM 病人(1.89 对 3.80 g/mL ) 相比的 DCM 病人是显著地更低的,并且在 6 月的后续(P=0.0151 ) 上减少了。中部的层次仍然是的 suPAR 提高了,暗示主要进行中的煽动性的过程。是在 GDF-15 和 H-FABP 由重要减少证明层次,在室的改变的减小和无临床症状的局部缺血能被假定。然而,血液动力学的应力(sST2 ) 的标记和发炎(suPAR ) 没在 CHF 病人在 6 月 Ivabradine 治疗以后显示出变化或前进。进一步的研究是必要的验证这些新奇心血管的 biomarkers 的临床的适用性。Peter JIRAK Dzeneta FEJZIC Vera PAAR Bernhard WERNLY Rudin PISTULLI Ilonka ROHM Christian JUNG Uta C HOPPE P Christian SCHULZE Michael LICHTENAUER Atilla YILMAZ Daniel KRETZSCHMAR 2018Acta Pharmacologica Sinica2018,39,7:31
2Factors associated with long-term survival after liver transplantation:A retrospective cohort study显示文摘AIM To identify predictive factors associated with long-term patient and graft survival(> 15 years) in liver transplant recipients.METHODS Medical charts of all de novo adult liver transplant recipients(n = 140) who were transplanted in Hamburg between 1997 and 1999 were retrospectively reviewed.In total,155 transplantations were identified in this time period(15 re-transplantations).Twenty-six orthotopic liver transplant(OLT) recipients were early lost to followup due to moving to other places within 1 year after transplantation.All remaining 114 patients were included in the analysis.The following recipient factors were analysed:Age,sex,underlying liver disease,pre-OLT body mass index(BMI),and levels of alanine aminotransferase(ALT),bilirubin,creatinine and gammaglutamyltransferase(gamma-GT),as well as warm and cold ischemia times.Furthermore,the following donor factors were assessed:Age,BMI,cold ischemia time and warm ischemia time.All surviving patients were followed until December 2014.We divided patients into groups according to their underlying diagnosis:(1) hepatocellularcarcinoma(n = 5,4%);(2) alcohol toxic liver disease(n = 25,22.0%);(3) primary sclerosing cholangitis(n = 6,5%);(4) autoimmune liver diseases(n = 7,6%);(5) hepatitis C virus cirrhosis(n = 15,13%);(6) hepatitis B virus cirrhosis(n = 21,19%);and(7) other(n = 35,31%).The group 'other' included rare diagnoses,such as acute liver failure,unknown liver failure,stenosis and thrombosis of the arteria hepatica,polycystic liver disease,Morbus Osler and Caroli disease.RESULTS The majority of patients were male(n = 70,61%).Age and BMI at the time point of transplantation ranged from 16 years to 69 years(median:53 years) and from 15 kg/m^2 to 33 kg/m^2(median:24),respectively.Sixty-six OLT recipients(58%) experienced a follow-up of 15 years after transplantation.Recipient's age(P = 0.009) and BMI(P = 0.029) were identified as risk factors for death by χ~2-test.Kaplan-Meier analysis confirmed BMI or age above the median as predictors of decreased long-term survival(P = 0.008 and P = 0.020).Hepatitis B as underlying disease showed a trend for improved long-term survival(P = 0.049,χ~2-test,P = 0.055;Kaplan-Meier analysis,Log rank).Pre-transplant bilirubin,creatinine,ALT and gamma-GT levels were not associated with survival in these patients of the pre-era of the model of end stage liver disease.CONCLUSION The recipients' age and BMI were predictors of longterm survival after OLT,as well as hepatitis B as underlying disease.In contrast,donors' age and BMI were not associated with decreased survival.These findings indicate that recipient factors especially have a high impact on long-term outcome after liver transplantation.Sven Pischke Marie C Lege Moritz von Wulffen Antonio Galante Benjamin Otto Malte H Wehmeyer Uta Herden Lutz Fischer Bjorn Nashan Ansgar W Lohse Martina Sterneck 2017World Journal of Hepatology2017,9,8:5
3Co-morbidities of vertiginous diseases显示文摘Jan C W Otmar B Uta F 2009BMC Neurol2009,9,:1
4Supply chain risk management : outlining an agenda for future research 显示文摘UTA J HELEN P MARTIN C 2003International Journal of Logistics : Research and Applications2003,6,4:1
5The outcome of tuberculosis in patients on chronic hemodialysis 显示文摘Taskapan H Utas C Oymak FS 2000Clin Nephrol2000,54,2:1
6Determination of microvessel density by quantitative real-time PCR in esophageal cancer:correlation with histologic methods,angiogenic growth factor expression,and lymph node metastasis显示文摘Sonja L Henning C Uta R 2007Clin Cancer Res2007,13,1:1
7The outcome of tuberculosis in patients on chronic hemodialysis显示文摘TASKAPAN H UTAS C OYMAK F S 2000Clin Nephrol2000,54,2:1
8Cashflow-at-risk and financial policy for electricity companies in the new world order显示文摘LaGATI'UTA D A STEIN J C TENNICAN M L 2000The Electricity Journal2000,13,10:1
9The outcome of tuberculosis in patients on chronic hemodialysis显示文摘Taskapan H Utas C Oymak FS 2000Clin Nephrol2000,54,:1
10Supply chain risk man- agement:outlining an agenda for future research 显示文摘UTA J HELEN P MARTIN C 2003International Journal of Logistics:Research & Applica- tions2003,6,4:1
11L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma显示文摘瞄准:在胰腺的神经内分泌肿瘤决定 L1 的表示并且相关它与这个肿瘤的分类。方法:我们回顾地在原发性瘤或转移的石蜡节上由免疫组织化学在胰腺的神经内分泌肿瘤的 63 种情况中分析了 L1 表示。染色被过氧化物酶技术对人的 L1 与单音的同种细胞的抗体 UJ127.11 执行。所有肿瘤被分类根据分类同样区分得好的神经内分泌肿瘤和癌或糟糕区分的神经内分泌癌。结果:L1 在 5 被检测(7.9%) 63 个胰腺的神经内分泌肿瘤。(44.4%) 四 9 糟糕区分的癌表示了 L1。相反,仅仅(1.9%) 1 为 L1 54 个区分得好的肿瘤或癌是积极的。没有表示在正常胰腺的织物的 Langerhans 小岛房间被发现。生气桌子分析显示出在 L1 表示和胰(P<0.01 ) 的神经内分泌肿瘤的分类之间的一个重要协会。结论:L1 明确地在被知道有最糟的预后的糟糕区分的胰腺的神经内分泌癌被表示。L1 可能是为与胰腺的神经内分泌癌诊断的病人的风险预言的一个标记。Jussuf T Kaifi Ulrich Zinnkann Emre F Yekebas Paulus G Schurr Uta Reichelt Robin Wachowiak Henning C Fiegel Susann Petri Melitta Schachner Jakob RIzbicki 2006World Journal of Gastroenterology2006,12,1:1
12Determination of microvessel density by quantitative real-time PCR in esophageal cancer: Correlation with histologic methods, angiogenic growth factor expression, and lymph node mctastasis显示文摘Sonja L Henning C Uta R 2007Clinical Cancer Research2007,13,:1
13Improvement ofthyroid hormone profile and thyrotrophin ( TSH) surgealterations in hemodialysis patients on erythropoietintreatment显示文摘UTAS C TASKAPAN H OYMAK O 2001Clin Nephrol2001,55,6:1
14Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry显示文摘Sven B Uta C Georg M F 2005Clin Chem2005,51,6:1
15Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ ionization time of flight mass spectrometry 显示文摘Sven B Uta C Georg MF 2005Clin Chem2005,6,:1
16Induction of vascular endothelial growth factor receptor expression on tumor microvasculature as a new progression marker in human cutaneous melanoma显示文摘Ruud C Lia S Uta BH 2002Cancer Res2002,62,23:1
17Control of plas- ma glucose with somatostatin analogue ( SMS 201-995 ) during surgical removal of insulinomas 显示文摘Utas C Kelestimur F Boyacil A 1993Postgrad Med J1993,69,818:1
18Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry显示文摘Sven B Uta C Georg MF 2005Clin Chem2005,6,:1
19The outcome of tubercu- lo2sis in patients on chronic hemodialysis 显示文摘Taskapan H Utas C Oymak FS 2010Clin Nephrol2010,54,2:1
20Supply chain risk management:outlining an agenda for future research显示文摘UTA J HELEN P MARTIN C 2003International Journal of Logistics:Research and Applications2003,6,4:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费